MedPath

VICAL

๐Ÿ‡ซ๐Ÿ‡ทFrance
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

13

Active:0
Completed:10

Trial Phases

3 Phases

Phase 1:5
Phase 2:5
Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)โ€ข Click on a phase to view related trials

Phase 1
5 (38.5%)
Phase 2
5 (38.5%)
Phase 3
3 (23.1%)

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Phase 2
Terminated
Conditions
Invasive Pulmonary Aspergillosis
Invasive Aspergillosis
First Posted Date
2017-10-31
Last Posted Date
2019-02-27
Lead Sponsor
Vical
Target Recruit Count
4
Registration Number
NCT03327727
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

UC San Diego Moores Cancer Center, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States

and more 25 locations

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

Phase 2
Completed
Conditions
Herpes Genitalis
First Posted Date
2016-07-19
Last Posted Date
2019-02-27
Lead Sponsor
Vical
Target Recruit Count
261
Registration Number
NCT02837575
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Alabama Vaccine Research Clinic at University of Alabama at Birmingham, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Medical Center for Clinical Research, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

QPS Broward Research, Hollywood, Florida, United States

and more 12 locations

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Phase 1
Completed
Conditions
Genital Herpes Simplex Type 2
First Posted Date
2014-01-08
Last Posted Date
2019-02-27
Lead Sponsor
Vical
Target Recruit Count
165
Registration Number
NCT02030301
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Alabama Vaccine Research Clinic, Birmingham, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Broward Research Group, Hollywood, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Indiana University Infectious Diseases Research, Indianapolis, Indiana, United States

and more 4 locations

Pandemic Influenza Plasmid DNA Vaccines (Needle)

Phase 1
Completed
Conditions
Influenza
First Posted Date
2008-07-03
Last Posted Date
2009-02-12
Lead Sponsor
Vical
Target Recruit Count
56
Registration Number
NCT00709800
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Accelovance, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

SNBL, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

SUNY at Stonybrook, Stony Brook Medical Center, Stony Brook, New York, United States

Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)

Phase 1
Completed
Conditions
Influenza
First Posted Date
2008-06-10
Last Posted Date
2019-02-27
Lead Sponsor
Vical
Target Recruit Count
47
Registration Number
NCT00694213
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Accelovance, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

SNBL, Baltimore, Maryland, United States

๐Ÿ‡บ๐Ÿ‡ธ

SUNY at Stonybrook, Stony Brook Medical Center, Stony Brook, New York, United States

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.